Literature DB >> 27112649

Repair of Partial Atrioventricular Septal Defect: Age and Outcomes.

Paul J Devlin1, Carl L Backer2, Osama Eltayeb3, Michael C Mongé3, Amanda L Hauck4, John M Costello4.   

Abstract

BACKGROUND: We evaluated the outcomes of patients undergoing surgical repair of partial atrioventricular septal defect (AVSD) and analyzed the effect of age on outcome.
METHODS: In this single-center retrospective study, we included all children who underwent repair of partial AVSD between 1990 and 2014. We divided the patients into 4 age quartiles (first quartile: 0-0.75 years, n = 22; second quartile: 0.75-1.5 years, n = 21; third quartile: 1.5-3.75 years, n = 22; and fourth quartile: >3.75 years, n = 21). These quartiles were evaluated for their association with the time-to-event outcomes of survival, freedom from left atrioventricular valve regurgitation (LAVVR), and freedom from reoperation using log-rank analysis.
RESULTS: During the study period, 86 patients underwent partial AVSD repair at a median age of 1.5 years. There were no operative deaths and 2 late deaths (unknown cause and trauma). There were 13 reoperations. The most common cause of reoperation was left ventricular outflow tract obstruction (LVOTO) (5 patients [first quartile, 2 cases; second quartile, 1 case; third quartile, 2 cases, and fourth quartile, 0 cases]). LAVV reoperation for insufficiency or stenosis was performed in 4 patients (first quartile, 1 case; second quartile, 1 case; third quartile, 1 case; and fourth quartile, 1 case). Two patients underwent pacemaker placement (second quartile, 1 case and fourth quartile, 1 case). There were no statistically significant differences in the most common complications-LVOTO, LAVVR, and AV heart block-between the 4 age quartiles. Median follow-up was 7.1 years (interquartile range [IQR], 0.8-11.4 years). On echocardiography, 72 patients (84%) had less than or equal to mild LAVVR, 8 (9%) patients had mild to moderate LAVVR, 5 (6%) patients had moderate LAVVR, and 1 (1%) patient had severe LAVVR. Age at repair had no significant association with degree of late AV valve insufficiency.
CONCLUSIONS: Results of partial AVSD repair at a median age of 1.5 years are excellent. Operating at this age is not associated with increased mortality, reoperation, or LAVVR.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27112649     DOI: 10.1016/j.athoracsur.2016.01.085

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Bradyarrhythmias in Repaired Atrioventricular Septal Defects: Single-Center Experience Based on 34 Years of Follow-Up of 522 Patients.

Authors:  Corrado Di Mambro; Camilla Calvieri; Massimo Stefano Silvetti; Ilaria Tamburri; Salvatore Giannico; Anwar Baban; Sonia Albanese; Gianluca Brancaccio; Adriano Carotti; Fiore Salvatore Iorio; Fabrizio Drago
Journal:  Pediatr Cardiol       Date:  2018-06-13       Impact factor: 1.655

Review 2.  EDUCATIONAL SERIES IN CONGENITAL HEART DISEASE: Echocardiographic assessment of left to right shunts: atrial septal defect, ventricular septal defect, atrioventricular septal defect, patent arterial duct.

Authors:  Antigoni Deri; Kate English
Journal:  Echo Res Pract       Date:  2018-02-05

3.  Management of Congenital Heart Disease: State of the Art; Part I-ACYANOTIC Heart Defects.

Authors:  P Syamasundar Rao
Journal:  Children (Basel)       Date:  2019-03-08

4.  Repair of partial atrioventricular canal defect in adult patients: two-year follow-up outcomes of a retrospective study.

Authors:  Lingyun Song; Yunfei Ling; Qi An
Journal:  J Cardiothorac Surg       Date:  2019-06-11       Impact factor: 1.637

5.  Challenges in the Surgical Treatment of Atrioventricular Septal Defect in Children With and Without Down Syndrome in Romania-A Developing Country.

Authors:  Ioana-Cristina Olariu; Anca Popoiu; Andrada-Mara Ardelean; Raluca Isac; Ruxandra Maria Steflea; Tudor Olariu; Adela Chirita-Emandi; Ramona Stroescu; Mihai Gafencu; Gabriela Doros
Journal:  Front Pediatr       Date:  2021-07-07       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.